<DOC>
	<DOCNO>NCT01041027</DOCNO>
	<brief_summary>This phase II trial study well radiation therapy , paclitaxel , carboplatin work treat patient high-risk endometrial cancer . Radiation therapy use high energy x ray kill tumor cell . Drugs use chemotherapy , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell , stop divide stop spread . Giving radiation therapy chemotherapy may kill tumor cell .</brief_summary>
	<brief_title>Radiation Therapy , Paclitaxel , Carboplatin Treating Patients With High-Risk Endometrial Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate progression-free survival . II . To assess document location disease recurrence ( distant v local v ) use treatment regimen . II . To evaluate toxicity radiation therapy `` sandwich '' cycle paclitaxel/carboplatin chemotherapy patient high-risk endometrial cancer . III . To evaluate association cancer recurrence tumor tissue expression level insulin-like growth factor-I ( IGF-I ) , IGF-II , insulin-like growth factor bind protein 1 ( IGFBP-1 ) -3 , insulin receptor , IGF-I receptor , estrogen receptor , progesterone receptor . OUTLINE : CHEMOTHERAPY ( week 1-9 , 13-21 ) : Patients receive paclitaxel intravenously ( IV ) 3 hour carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 3 course week 1-9 3 course week 13-21 . RADIATION THERAPY ( week 8-13 8-15 ) : Patients stage I disease undergo high dose rate ( HDR ) brachytherapy weekly total 5 fraction week 8-13 . All patient undergo external beam radiation therapy ( EBRT ) daily ( QD ) 5 day week total 25 fraction week 8-12 HDR brachytherapy weekly total 3 fraction week 13-15 . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologicallydocumented highrisk endometrioid adenocarcinoma visible residual disease , define follow criterion : Surgical stage I disease &lt; 50 myometrial invasion grade 3 tumor ( IAG3 ) lymphovascular space involvement ; Surgical stage I disease &gt; = 50 % myometrial invasion grade 2 3 tumor ( IBG2 , IBG3 ) ; Any surgical stage II disease ( II ) ; Any surgical stage III disease ( IIIA , IIIB , IIIC ) ; Any surgical stage IV disease residual macroscopic tumor Surgical stag include total abdominal hysterectomy , bilateral salpingooophorectomy , peritoneal washing , lymph node sampling per standard Gynecologic Oncology Group ( GOG ) criterion Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 Written voluntary inform consent Serum glutamic oxaloacetic transaminase ( SGOT ) and/or serum glutamate pyruvate transaminase ( SGPT ) &gt; 2.5 time institutional upper limit normal Total serum bilirubin &gt; 1.5 mg/dl History chronic active hepatitis Serum creatinine &gt; 2.0 mg/dl Platelets &lt; 100,000/mm^3 Absolute neutrophil count ( ANC ) &lt; 1500/mm^3 Hemoglobin &lt; 8.0 g/dl ( patient may transfuse prior study entry ) Patient severe uncontrolled concurrent medical disease ( e.g . uncontrolled diabetes , unstable angina , myocardial infarction within 6 month , congestive heart failure , etc . ) Patient prior chemotherapy radiotherapy pelvic malignancy Patients dementia alter mental status would prohibit give understand informed consent time study entry Patients history cancer exception nonmelanoma skin cancer exclude evidence malignancy present within past five year</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>